

Hepatocarcinoma

Adriamicina

Adriamicina: 20–30 mg/m² IV semanalmente Ref. (1)

Cisplatina

Cisplatina: 80 mg/m² IV D1, a cada 28 dias Ref. (2)

Capecitabina

Capecitabina: 1,000 mg/m² VO BID D1–14
a cada 21 dias Ref. (3)

Sorafenibe

Sorafenibe: 400mg VO BID por dia Ref. (4)

Capecitabina + Cisplatina

Capecitabina: 2000mg/m²/dia, BID, VO, D1 a D14
Cisplatina: 60mg/m² IV D1
a cada 3 semanas Ref. (5)

PIAF

Cisplatina: 20mg/m² IV D1 a D4
Interferon alfa 2b 5MU/m² SC D1 a D4
Doxorrubicina: 40mg/m² IV D1
5-Fluorouracil: 400mg/m² IV D1 a D4
a cada 3 semanas. Ref. (6)

Tamoxifeno

Tamoxifeno: 20mg VO por dia Ref. (7)

1. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994;12:1323–1334.

2. Okada S, *et al.* A phase 2 study of cisplatin in patients with hepatocellular carcinoma. *Oncology* 1993;50:22–26.
3. Aguayo A, *et al.* Nonsurgical treatment of hepatocellular carcinoma. *Semin Oncol* 2001;28:503–513.
4. Ilovet JM. Sorafenib in advanced hepatocellular Carcinoma. *N Engl J Med* 2008; 359:378-390.
5. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, *et al.* Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. *Ann Oncol.* 2009 Aug; 20(8):1402-7.
6. Yeo W, Mok TS, Zee B, Leung TW *et al.* A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. *J Natl Cancer Inst.* 2005 Oct 19;97(20):1532-8.
7. Barbare JC, Bouché O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. *J Clin Oncol.* 2005 Jul 1; 23(19):4338-46.